Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding
Nucleic acid aptamers are ssDNA or ssRNA fragments that specifically recognize targets. However, the pharmacodynamic properties of natural aptamers consisting of 4 naturally occurring nucleosides (A, G, C, T/U) are generally restricted for inferior binding affinity than the cognate antibodies. The d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2023.1091809/full |
| _version_ | 1797896089684148224 |
|---|---|
| author | Zefeng Chen Zefeng Chen Hang Luo Hang Luo Amu Gubu Amu Gubu Sifan Yu Huarui Zhang Hong Dai Hong Dai Yihao Zhang Baoting Zhang Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang |
| author_facet | Zefeng Chen Zefeng Chen Hang Luo Hang Luo Amu Gubu Amu Gubu Sifan Yu Huarui Zhang Hong Dai Hong Dai Yihao Zhang Baoting Zhang Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang |
| author_sort | Zefeng Chen |
| collection | DOAJ |
| description | Nucleic acid aptamers are ssDNA or ssRNA fragments that specifically recognize targets. However, the pharmacodynamic properties of natural aptamers consisting of 4 naturally occurring nucleosides (A, G, C, T/U) are generally restricted for inferior binding affinity than the cognate antibodies. The development of high-affinity modification strategies has attracted extensive attention in aptamer applications. Chemically modified aptamers with stable three-dimensional shapes can tightly interact with the target proteins via enhanced non-covalent bonding, possibly resulting in hundreds of affinity enhancements. This review overviewed high-affinity modification strategies used in aptamers, including nucleobase modifications, fluorine modifications (2′-fluoro nucleic acid, 2′-fluoro arabino nucleic acid, 2′,2′-difluoro nucleic acid), structural alteration modifications (locked nucleic acid, unlocked nucleic acid), phosphate modifications (phosphorothioates, phosphorodithioates), and extended alphabets. The review emphasized how these high-affinity modifications function in effect as the interactions with target proteins, thereby refining the pharmacodynamic properties of aptamers. |
| first_indexed | 2024-04-10T07:36:09Z |
| format | Article |
| id | doaj.art-f336ff8690354fe8abbf208b6b1c734a |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-04-10T07:36:09Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-f336ff8690354fe8abbf208b6b1c734a2023-02-23T12:43:32ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2023-02-011110.3389/fcell.2023.10918091091809Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bondingZefeng Chen0Zefeng Chen1Hang Luo2Hang Luo3Amu Gubu4Amu Gubu5Sifan Yu6Huarui Zhang7Hong Dai8Hong Dai9Yihao Zhang10Baoting Zhang11Yuan Ma12Yuan Ma13Yuan Ma14Aiping Lu15Aiping Lu16Aiping Lu17Ge Zhang18Ge Zhang19Ge Zhang20Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaAptacure Therapeutics Limited, Kowloon, Hong Kong SAR, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaSchool of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, Hong Kong SAR, ChinaNucleic acid aptamers are ssDNA or ssRNA fragments that specifically recognize targets. However, the pharmacodynamic properties of natural aptamers consisting of 4 naturally occurring nucleosides (A, G, C, T/U) are generally restricted for inferior binding affinity than the cognate antibodies. The development of high-affinity modification strategies has attracted extensive attention in aptamer applications. Chemically modified aptamers with stable three-dimensional shapes can tightly interact with the target proteins via enhanced non-covalent bonding, possibly resulting in hundreds of affinity enhancements. This review overviewed high-affinity modification strategies used in aptamers, including nucleobase modifications, fluorine modifications (2′-fluoro nucleic acid, 2′-fluoro arabino nucleic acid, 2′,2′-difluoro nucleic acid), structural alteration modifications (locked nucleic acid, unlocked nucleic acid), phosphate modifications (phosphorothioates, phosphorodithioates), and extended alphabets. The review emphasized how these high-affinity modifications function in effect as the interactions with target proteins, thereby refining the pharmacodynamic properties of aptamers.https://www.frontiersin.org/articles/10.3389/fcell.2023.1091809/fullaptamerchemical modificationhigh affinitynon-covalent bondinginteraction |
| spellingShingle | Zefeng Chen Zefeng Chen Hang Luo Hang Luo Amu Gubu Amu Gubu Sifan Yu Huarui Zhang Hong Dai Hong Dai Yihao Zhang Baoting Zhang Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding Frontiers in Cell and Developmental Biology aptamer chemical modification high affinity non-covalent bonding interaction |
| title | Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding |
| title_full | Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding |
| title_fullStr | Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding |
| title_full_unstemmed | Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding |
| title_short | Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding |
| title_sort | chemically modified aptamers for improving binding affinity to the target proteins via enhanced non covalent bonding |
| topic | aptamer chemical modification high affinity non-covalent bonding interaction |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2023.1091809/full |
| work_keys_str_mv | AT zefengchen chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT zefengchen chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT hangluo chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT hangluo chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT amugubu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT amugubu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT sifanyu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT huaruizhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT hongdai chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT hongdai chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT yihaozhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT baotingzhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT yuanma chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT yuanma chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT yuanma chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT aipinglu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT aipinglu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT aipinglu chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT gezhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT gezhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding AT gezhang chemicallymodifiedaptamersforimprovingbindingaffinitytothetargetproteinsviaenhancednoncovalentbonding |